Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)-Reference-Cited by-同舟云学术

Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)

Published:2021-08-23 Issue:23 Volume:127 Page:4421-4431
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Kantarjian Hagop M.¹^ORCID,Begna Kebede H.²^ORCID,Altman Jessica K.³,Goldberg Stuart L.⁴^ORCID,Sekeres Mikkael A.⁵^ORCID,Strickland Stephen A.⁶^ORCID,Arellano Martha L.⁷^ORCID,Claxton David F.⁸^ORCID,Baer Maria R.⁹^ORCID,Gautier Marc¹⁰,Berman Ellin¹¹^ORCID,Seiter Karen¹²^ORCID,Solomon Scott R.¹³^ORCID,Schiller Gary J.¹⁴^ORCID,Luger Selina M.¹⁵^ORCID,Butrym Aleksandra¹⁶^ORCID,Gaidano Gianluca¹⁷^ORCID,Thomas Xavier G.¹⁸^ORCID,Montesinos Pau¹⁹^ORCID,Rizzieri David A.²⁰^ORCID,Quick Donald P.²¹,Venugopal Parameswaran²²^ORCID,Gaur Rakesh²³^ORCID,Maness Lori J.²⁴,Kadia Tapan M.¹^ORCID,Ravandi Farhad¹^ORCID,Buyse Marc E.²⁵^ORCID,Chiao Judy H.²⁶^ORCID

Affiliation:

1. Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas

2. Division of Hematology Mayo Clinic Rochester Minnesota

3. Department of Medicine Northwestern University Chicago Illinois

4. Hackensack University Medical Center Hackensack New Jersey

5. Hematologic Oncology and Blood Disorders Cleveland Clinic Cleveland Ohio

6. Vanderbilt‐Ingram Cancer Center Nashville Tennessee

7. Hematology/Oncology Emory University School of Medicine Atlanta Georgia

8. Penn State Milton S. Hershey Medical Center Hershey Pennsylvania

9. University of Maryland Greenebaum Comprehensive Cancer Center Baltimore Maryland

10. Dartmouth‐Hitchcock Medical Center Lebanon New Hampshire

11. Memorial Sloan Kettering Cancer Center New York New York

12. Department of Medicine New York Medical College Valhalla New York

13. Northside Hospital Cancer InstituteLeukemia Program Atlanta Georgia

14. Hematological Malignancy/Stem Cell Transplant Program David Geffen School of Medicine at the University of California Los Angeles California

15. Department of Hematology/Oncology Abramson Cancer Center University of Pennsylvania Philadelphia Pennsylvania

16. Department of Hematology, Blood Neoplasms, and Bone Marrow Transplantation Wroclaw Medical University Wroclaw Poland

17. Division of Hematology Maggiore della Carita University Hospital Novara Italy

18. Hematology South Hospital Center Lyon France

19. La Fe University and Polytechnic Hospital Valencia Spain

20. Department of Medicine Duke University Medical Center Durham North Carolina

21. Joe Arrington Cancer Center Lubbock Texas

22. Department of Medicine, Hematology, and Oncology Rush University Medical Center Chicago Illinois

23. St Luke's Cancer Institute Kansas City Missouri

24. Division of Hematology‐Oncology Department of Internal Medicine University of Nebraska Medical Center Omaha Nebraska

25. International Drug Development Institute Louvain‐la‐Neuve Belgium

26. Cyclacel Limited Dundee United Kingdom

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33828

Reference26 articles.

1. Drug therapy for acute myeloid leukemia

2. The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

3. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges

4. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

5. National Cancer Institute (NCI).NCI Surveillance Epidemiology and End Results (SEER) Program. Cancer Statistics Review (CSR) 1975‐2014. Table 13.14: Leukemia. Accessed May 13 2018.https://seer.cancer.gov/csr/1975_2015/results_single/sect_13_table.14.pdf

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review;Future Oncology;2023-04

2. Non-intensive acute myeloid leukemia therapies for older patients;Expert Review of Hematology;2023-03-02

3. Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia;Cancer;2023-01-30

4. Venetoclax in combination with nucleoside analogs in acute myelogenous leukemia;Current Opinion in Oncology;2022-07-16